Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (6)

1

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052) : Outcomes in Older Patients by Age and Performance Status

enthalten in: European urology oncology | 2020

von Grivas, P. | Plimack, E. | Balar, A. | +11

2

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

enthalten in: The lancet / Oncology | March 2020

von Garassino, M. | Gadgeel, S. | Esteban, E. | +16

3

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study : evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

enthalten in: European journal of cancer | January 2018

von Schneeweiss, A. | Chia, S. | Hickish, T. | +6

4

First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction

enthalten in: Journal of clinical oncology | February 8, 2016

von Gertz, M. | Landau, H. | Comenzo, R. | +11

5

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer : results from AVADO

enthalten in: European journal of cancer | 15 July 2011

von Pivot, X. | Schneeweiss, A. | Verma, S. | +8

6

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

enthalten in: Journal of clinical oncology | July 10 2010

von Miles, D. | Chan, A. | Dirix, L. | +13

1
[1]